Driving the Future of Innovation in Cell & 유전자 치료제, Together

Partner | DeciBio Consulting

  Carl leads DeciBio’s advanced therapies practice. He brings experience across biopharma, manufacturing / bioprocessing, and supply chain considerations for his clients. He has executed on projects ranging from pipeline prioritization / life cycle management, indication road mapping, growth strategy, and M&A projects across healthcare, life science tools, and pharma (cell and gene therapies). Carl holds a B.S. from the university of California, Berkeley, and a Ph.D. from MIT where he trained with Professor Robert Langer.

Founder and Senior Advisor | Biomatria

Basak Clements, PhD, is the Founder and Senior Advisor at Biomatria, a scientific consultancy specializing in materials science and management for the biopharmaceutical and advanced therapy industries. Previously, Basak served as Global Head/Senior Director of Cell and 유전자 치료제 Materials Science at Roche/Genentech, and in various roles at Johnson & Johnson and Amgen.

PhD | University College London

Pierre is a Biochemical Engineering PhD researcher at the University College London. His research, conducted in close collaboration with 싸토리우스, focuses on the development and optimisation of CAR-T therapy manufacturing processes in single-use stirred-tank bioreactors. He specialises in perfusion intensification and bioprocess scale-up, aiming to enhance the efficiency and scalability of CAR-T cell production processes.

Assistant Professor |     Stanford Department of Bioengineering 

Mark Skylar-Scott is an Assistant Professor of Bioengineering at Stanford, a member of the BASE Initiative at the Children’s Heart Center, and a Chan-Zuckerberg Biohub Investigator. He received the NIH Director’s New Innovator Award to accelerate organ engineering by scaling cell production and advancing 3D printing materials and hardware.

Director of Innovation and Platform for Cell & 유전자 치료제 | Elevate Bio

  Dr. Chesney Michels (PhD) serves as Director of ElevateBio’s PD Platform and Emerging Technology team. He is focused on supporting clients with cells from pre-clinical development of NextGen therapeutics, and evaluating new process technologies, instruments and reagents that have the potential to disrupt the CGT space, from early stages through to commercialization.

Vice President, Cellular Therapies Operations | Dana Farber  

Julie Porter has served as an administrative leader in academic medicine cancer centers across the country for more than 15 years in a variety of roles, including quality, operations, and strategy.  She is based in Boston, Massachusetts. 

Technical Director, DFCI Immune Effector 세포 치료제 Program | Dana Farber  

With clinical training in medical hematology/oncology and a PhD in Immunobiology, Dr. Nikiforow leads 세포 치료제 program initiatives at Dana-Farber Cancer Institute as a stem cell transplant clinician, Technical Director of the Immune 작동세포 Program and Medical Director of CMCF, one of the nation’s largest academic cell manufacturing facilities.

Founder & CEO Redline Bioadvisors, Chief Commercialization Officer ISCT | Redline Bioadvisors

An entrepreneurial and strategic international business leader, Phil serves as a strategic advisor to investors, life sciences startups, and advanced therapies organizations through his Redline Bioadvisors entity.  Prior to founding Redline, Phil was CTO and Partner at Gamma Biosciences, a KKR life sciences tools investment, where he was responsible for technical diligence, as well as guiding operational, R&D and strategic initiatives carried out at portfolio companies.  Phil received his Ph.D. in Biochemistry and Molecular Biology at Georgetown University Medical Center, with research focused in molecular oncology.  

Managing Director, Cell & 유전자 치료제 CoE Lead | Accenture  

Sanjay Srivastava leads strategic healthcare transformations at Accenture, drawing on over a decade in consulting, including his role as Senior Manager at Deloitte. He focuses on innovation, change management, and patient-centered solutions. As an HBR Advisory Council member and Vitalant board member, he champions open innovation and improved access to advanced therapies.

Chief Scientific Officer | Kiji Therapeutics  

Dr. Ting is the CSO for Kiji Therapeutics, with over 20 years of industry experience. Prior to joining Kiji Therapeutics, he served as Program Leader in Oncology 세포 치료제 Innovation at Takeda. He was also the CSO for Bone Therapeutics and the Vice President of Regenerative Medicine at Athersys.

Head of Process Analytics and Data Science | ReciBio  

Dr. Edita Botonjic-Sehic is a Head of process analytics and data science at ReciBioPharm where she provides technical insight, strategic conceptualization and implementation of PAT, data engineering and data science; she has 20+ years of experience in advanced PAT and data science techniques improving manufacturing concepts in pharmaceutical/therapeutics development.

Chief Scientific Officer | ReciBio  

Aaron B. Cowley, PhD, MBA, is the Chief Scientific Officer at ReciBioPharm (formerly Arranta Bio), the biologics division of ReciPharm. He leads the vision and execution of the company’s continuous manufacturing platform for xRNA and is a founding member of the MIT Center for Continuous mRNA Manufacturing.

Director, Institute for NanoBioTechnology; Professor, Materials Sci & Eng, and Biomed Eng |  Johns Hopkins University  

Dr. Hai-Quan Mao’s research focuses on nanofiber-hydrogel  composites for tissue repair, machine-learning-guided lipid nanoparticles for gene delivery, and immuno-engineering matrices. He is a Fellow of the National Academy of Inventors and the American Institute for Medical and Biological Engineering, and an associate editor of Biomaterials.

Senior Vice President of Product & Strateg | G-CON  

Dennis Powers is the Senior Vice President of Product &

Head of Process Development | Matica Biotechnology

Trent Lyman is Head of Process Development at Matica Biotechnology with nearly 25 years’ experience of biopharmaceutical innovation. He has led teams advancing vaccines, cell lines, and 바이러스 벡터 platforms, with a focus on scalable solutions that strengthen global health and enable next-generation gene therapies.

Head of Product Development 세포주, Media and Testing Solutions (CMTS) | 싸토리우스  

Sandra holds a PhD in Biotechnology and more than 12 years of experience in the biotech industry. After leading R&D teams focusing on cell culture and media development as part of the Xell management team, she supported the acquisition by 싸토리우스 in 2021. Her current global role in 싸토리우스 is Head of Product Development 세포주, Media and Testing Solutions, developing products for protein- as well as viral-based therapies, including AAV and LV vectors.

Principal Scientist, PD and Clinical Production Service for Advanced Therapies | 싸토리우스

Sarah Gilpin joined 싸토리우스 in 2024, with a background in stem cell and developmental biology, cell biomanufacturing, tissue engineering, and regenerative medicine.  She obtained her PhD at the University of Toronto, focused on stem cell biomarkers in organ transplantation, and completed post-doctoral training at Harvard Medical School in whole organ engineering, before holding scientific positions at the Wyss Institute for Biologically Inspired Engineering, United Therapeutics Corporation, and Astellas Pharma, leading teams in microphysiological models, stem cell production, and translational stem cell therapies.

Head of Quality and Regulatory Affairs, 싸토리우스 BPS| 싸토리우스

Dr. Doli Patel is the Head of Quality and RA at 싸토리우스 BPS. Her blend of experience of > 25 years in ATMPs and medical devices, as quality executive, COO and CMC Director, covers global regulatory landscape. Her focus brings smart solutions to accelerate approvals, addressing Cost of Compliance.

Head of Customer & Industry Advocacy Strategy BPS | 싸토리우스

Miriam Monge has over 25 years biopharmaceutical industry experience starting her career as Head of Marketing for Stedim Biosystems. Since joining 싸토리우스 Miriam has had a strong focus on single-use technologies and process integration, playing multiple process and modality focused roles. She is heavily involved in industry advocacy topics chairing committees guiding 싸토리우스 engagement within industry associations such as BioPhorum, ISPE where she founded & chaired the SU community of practice, PDA, and NIMBL. Miriam has authored 50+ publications on single-use technologies and is a long-term editorial advisor for Bioprocess International.

Gain exclusive access to the latest advancements and strategies in CGT before they become mainstream.

Connectwith industry leaders and peers to share insights, collaborate on ideas, and build lasting professional relationships. 

Take advantage of our networking reception while enjoying catered food and evening entertainment.